TABLE 1.
Diagnostic performance of the rapid test for detection of the CzIE in MSSA isolates recovered from selected hospitals in Latin America and the United States
| Country (no. of isolates) | CzIE by broth microdilution “gold standard” |
% sensitivity (95% CI) | % specificity (95% CI) | |||||
|---|---|---|---|---|---|---|---|---|
| Present |
Absent |
|||||||
| No. (%) of MSSA | Rapid test |
No. (%) of MSSA | Rapid test |
|||||
| No. (%) MSSA positive | No. (%) MSSA negative | No. (%) MSSA negative | No. (%) MSSA positive | |||||
| Argentina (n = 82) | 45 (55) | 40 (89) | 5 (11) | 37 (45) | 34 (92) | 3 (8) | 88.9 (76.0–96.3) | 91.9 (78.1–98.3) |
| Brazil (n = 75) | 23 (31) | 14 (61) | 9 (39) | 52 (69) | 42 (81) | 10 (19) | 60.87 (38.5–80.3) | 80.8 (67.5–90.4) |
| Colombia (n = 186) | 73 (39) | 62 (85) | 11 (15) | 113 (61) | 103 (91) | 10 (9) | 84.9 (74.6–92.2) | 91.2 (84.3–95.7) |
| Chile (n = 85) | 26 (31) | 22 (85) | 4 (15) | 59 (69) | 49 (83) | 10 (17) | 91.2 (84.3–95.7) | 83.1 (71.0–91.6) |
| Ecuador (n = 64) | 26 (41) | 21 (81) | 5 (19) | 38 (59) | 35 (92) | 3 (8) | 80.8 (60.7–93.5) | 92.1 (78.6–98.3) |
| Guatemala (n = 55) | 23 (42) | 19 (83) | 4 (17) | 32 (58) | 27 (84) | 5 (16) | 82.6 (61.2–95.1) | 84.4 (67.2–94.7) |
| Mexico (n = 10) | 4 (40) | 4 (100) | 0 | 6 (60) | 5 (83) | 1 (17) | 100 (39.76–100) | 83.3 (35.9–99.6) |
| Peru (n = 60) | 22 (37) | 20 (91) | 2 (9) | 38 (63) | 35 (92) | 3 (8) | 90.9 (70.8–98.9) | 92.1 (78.6–98.3) |
| Venezuela (n = 23) | 10 (43) | 6 (60) | 4 (40) | 13 (57) | 13 (100) | 0 | 60 (26.2–87.8) | 100 (75.3–100) |
| USA (n = 49) | 5 (10) | 4 (80) | 1 (20) | 44 (90) | 41 (93) | 3 (7) | 80 (28.4–99.5) | 93.2 (81.3–98.6) |
| Total (n = 689) | 257 (37) | 212 (82) | 45 (18) | 432 (63) | 384 (89) | 48 (11) | 82.5 (77.3 86.9) | 88.9 (85.5–91.7) |